First-line treatment of lung cancer Sanofi / regenerative meta-PD-1 inhibitor phase 3 clinical data positive

Lung cancer is the leading cause of cancer death, both worldwide and in ChinaMore than 780,000 people in China are diagnosed with lung cancer each year, and more than 620,000 people die as a resultLung cancer can be roughly divided into small cell lung cancer and NSCLC, NSCLC is the most common type of lung cancer, accounting for 80%-85% of the total number of lung cancerIn NSCLC patients, 25%-30% of scaly NSCLC patients and 70%-75% of non-scaly NSCLC patientsMost NSCLC patients are late at the time of diagnosis, with a five-year survival rate of only 10%Libtayo is an all-humanized anti-PD-1 monoclonal antibody developed by Sanofi and RegenerationIt helps the body's immune system kill tumor cells by blocking the PD-1 signaling pathwayPreviously, it has been approved in the United States, the European Union, Canada and Brazil for the treatment of metastatic skin squamous cell carcinoma (CSCC) or for localized advanced CSCC patients who cannot receive curative surgery or radiotherapyIn addition, Libtayo is treating patients with cervical cancer, head and neck squamous cell carcinoma, melanoma, colorectal cancer, prostate cancer, multiple myeloma, Hodgkin's lymphoma and non-Hodgkin lymphoma in clinical trialsin Phase 3 clinical trials of Patients with NSCLC with PD-L1 expression levels of 50% in Libtayo as a single-drug therapy, the participants had IIIB, IIIC or PHASE IV scaly or non-scaly NSCLC, were not suitable for chemotherapy and radiation therapy, and had not received systemic therapy for advanced diseasesA mid-stage analysis of the trial showed that 42 percent of PATIENTS TREATED WITH LIBTAYO HAD ORR compared to individual chemotherapy, which was very similar to the ORR (39 percent) achieved by Keytruda, which was becoming the standard nursing therapy for some lung cancer patients, in the previous three trials, compared with 22 percent in the chemotherapy grouplook forward to this PD-1 inhibitor can bring us more good news, for the vast number of lung cancer patients to provide more treatment options!References:s1 shttps://®Regeneron's Libtayo show rate in line with Keytruda's in first-line NSCLC, 2019, from https://